April 16, 2026 (MLN): S.G. Power Limited has approved a comprehensive strategic transformation to reposition itself as a healthcare-focused business, with an initial emphasis on pharmaceutical licensing, distribution, and trading.

The transition marks a shift toward a high-growth and resilient sector, underpinned by strong demand fundamentals and scalable revenue potential, with the company targeting near-term revenue generation alongside long-term expansion within the pharmaceutical ecosystem.

As part of the restructuring, the company will alter its Memorandum and Articles to enable operations across pharmaceuticals, healthcare, and allied sectors, while also pursuing a name change to align with its new business direction.

The registered office will be relocated from Sindh to Punjab, aligning the legal base with the company’s operational focus. In parallel, the authorized share capital will be increased to Rs800 million to support future capital raising initiatives and working capital requirements, the company's filing on PSX revealed today. 

The company will initiate the process of obtaining relevant regulatory approvals from the Drug Regulatory Authority of Pakistan, enabling its entry into the pharmaceutical supply chain, subject to completion of corporate amendments and shareholder approvals.

A distribution-led market entry strategy has been adopted to facilitate rapid entry with relatively low capital intensity, allowing the company to commence revenue-generating operations in the near term while building a scalable platform.

The board has also authorized the establishment of domestic and international subsidiaries and special purpose vehicles, along with the pursuit of strategic partnerships, distribution arrangements, and joint ventures with local and international pharmaceutical operators.

Execution of the transformation is targeted within a 90–120 day timeline, positioning the company to transition into an active and revenue-generating healthcare business with the potential to materially enhance its scale, earnings profile, and market positioning.

An extraordinary general meeting will be convened to seek shareholder approval for the proposed corporate restructuring, capital changes, and strategic initiatives.

Copyright